Zura Bio (NASDAQ:ZURA) Announces Quarterly Earnings Results

Key Points

• Zura Bio reported a quarterly loss of $0.21 per share, missing analysts’ consensus estimate of a $0.20 loss by $0.01.
• Shares opened 4.1% higher at $5.86, while the company’s market capitalization stood at approximately $556 million.
• Analyst sentiment remains mixed but leans positive, with an average “Moderate Buy” rating and a consensus price target of $10.75; institutional investors own 61.14% of the stock.

Zura Bio (NASDAQ:ZURA - Get Free Report) issued its quarterly earnings data on Tuesday. The company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.20) by ($0.01), Zacks reports.

Zura Bio Stock Up 4.1%

Shares of ZURA opened at $5.86 on Tuesday. The stock's fifty day simple moving average is $4.84 and its 200-day simple moving average is $5.41. The firm has a market capitalization of $556.09 million, a PE ratio of -5.41 and a beta of -0.02. Zura Bio has a 12-month low of $1.39 and a 12-month high of $7.44.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on ZURA shares. Weiss Ratings reiterated a "sell (d-)" rating on shares of Zura Bio in a research report on Monday, July 6th. Wedbush restated an "outperform" rating and issued a $15.00 price target on shares of Zura Bio in a research report on Wednesday, July 1st. William Blair initiated coverage on shares of Zura Bio in a research note on Wednesday, July 8th. They set an "outperform" rating on the stock. Finally, Wall Street Zen raised shares of Zura Bio from a "strong sell" rating to a "sell" rating in a report on Saturday, August 1st. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Zura Bio presently has an average rating of "Moderate Buy" and a consensus price target of $10.75.

Institutional Trading of Zura Bio

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. JPMorgan Chase & Co. boosted its stake in shares of Zura Bio by 78.7% in the 2nd quarter. JPMorgan Chase & Co. now owns 4,659,951 shares of the company's stock valued at $4,893,000 after purchasing an additional 2,052,732 shares during the last quarter. Siren L.L.C. acquired a new position in Zura Bio in the fourth quarter valued at approximately $6,812,000. VR Adviser LLC boosted its stake in Zura Bio by 15.4% in the fourth quarter. VR Adviser LLC now owns 5,345,115 shares of the company's stock valued at $28,008,000 after acquiring an additional 713,899 shares during the last quarter. Braidwell LP boosted its stake in Zura Bio by 28.6% in the fourth quarter. Braidwell LP now owns 3,180,389 shares of the company's stock valued at $16,665,000 after acquiring an additional 707,583 shares during the last quarter. Finally, Marshall Wace LLP grew its holdings in Zura Bio by 228.5% during the 4th quarter. Marshall Wace LLP now owns 877,763 shares of the company's stock worth $4,599,000 after acquiring an additional 610,563 shares during the period. 61.14% of the stock is owned by institutional investors.

Zura Bio Company Profile

Zura Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation protein bioconjugates for therapeutic and diagnostic applications. Leveraging a proprietary platform for site-specific incorporation of non-canonical amino acids, the company aims to create highly targeted conjugates that improve drug delivery, enhance imaging contrast, and reduce off-target toxicity. Zura Bio’s technology is designed to streamline the manufacturing process by enabling precise attachment of payloads—such as cytotoxic drugs or imaging agents—to protein scaffolds without affecting their native structure or function.

The company’s research and development activities center on expanding its platform across multiple therapeutic areas, including oncology, immunology and rare diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source